Scientists Find Key to Reversing Chemo-Resistant Cancer

Scientists at Duke-NUS Medical School have found the molecular switch that makes pancreatic cancer resist chemotherapy and figured out how to flip it back.

The discovery centers on a gene called GATA6 that keeps cancer cells organized and responsive to treatment. When GATA6 levels are high, tumors behave in a more structured way and chemotherapy works better.

But pancreatic cancer cells don't stay put. They shift between two states: a treatable "classical" form and an aggressive "basal" form that resists drugs.

The research team, led by Professor David Virshup, traced this deadly transformation to a chain reaction inside cancer cells. A mutated gene called KRAS, present in nearly all pancreatic cancers, sends constant growth signals through a partner protein called ERK.

When ERK becomes overactive, it shuts down GATA6 production. Without GATA6, cancer cells lose their structure, become more aggressive, and stop responding to chemotherapy.

Here's where it gets exciting: when researchers blocked the KRAS and ERK pathway, GATA6 levels bounced back. The cancer cells shifted back to their more organized state and became sensitive to chemotherapy again.

The team tested combining drugs that block this pathway with standard chemotherapy. The results were stronger than either treatment alone, but only when GATA6 was present.

This explains why some patients respond better to certain treatments and provides a roadmap for doctors to predict which patients might benefit most from combination therapy. The findings also support ongoing clinical trials testing new treatments that target KRAS and related pathways.

The Bright Side

Pancreatic cancer ranks as the fourth leading cause of cancer death in Singapore and remains one of the toughest cancers to treat worldwide. Symptoms appear late, and current treatments offer limited help for most patients.

But this research offers something rare in pancreatic cancer: a clear path forward. By understanding how tumors become resistant, doctors can potentially reverse that process and make existing drugs work better.

Professor Lok Sheemei, Duke-NUS' Interim Vice-Dean for Research, noted that these findings provide a scientific foundation for combining targeted therapies with existing drugs in a rational way.

The implications reach beyond pancreatic cancer. Many other cancers driven by KRAS mutations show similar behavior shifts, meaning this discovery could help researchers tackle therapy resistance across multiple cancer types.

For patients facing one of medicine's toughest battles, this breakthrough offers new ammunition in the fight.